BioSkryb Genomics, a pioneer in single-cell and ultra–low-input multi-omic solutions, announced the execution of an exclusive license to a patent co-owned by Stanford University and the Chan Zuckerberg Biohub San Francisco (CZ Biohub SF) covering a method for combined single-cell DNA methylation and genome variation analyses. The invention originated at Stanford and enables simultaneous, high-resolution readouts of genomic variants and DNA methylation from the same single cell using a non-destructive workflow that preserves DNA integrity.

The licensed technology will enable BioSkryb to create products that help researchers analyze epigenetic state and genetic change in the same single cell clarifying clonal evolution, resistance mechanisms, and rare-cell biology in areas such as oncology and neurology.

“Customers have been clear: they want detailed insights on both methylation and variants from the same cell, without compromising sample integrity,” said Suresh Pisharody, Chief Executive Officer, BioSkryb Genomics. “This license addresses that need directly and enables solutions for researchers to track clonal evolution, therapy resistance, and precursor lesions with the confidence that only same-cell insights can provide. BioSkryb aims to bring this exclusively licensed capability to market as quickly and efficiently as possible, after rigorous validation.”

Enabling New Biologies and Breakthroughs in Precision Medicine

• See what bulk misses: Tie methylation dynamics to specific variants in the same cell to pinpoint rare subclones early and track their trajectories under treatment or disease progression.
  
  
• Make translational decisions with greater context: Connect genetic change and epigenetic state over time to inform therapy selection, MRD strategies, and progression risk in high-heterogeneity diseases.
  
  
• Work confidently with scarce samples: Apply a non-destructive approach that preserves material important for fine-needle aspirates (FNA) and limited tissue or blood while enabling downstream analysis and validation.

Looking ahead, BioSkryb’s roadmap includes a modular product architecture enabling customers, for the first time, to analyze genomic variants, methylation, the transcriptome, and the surface proteome from the same cell within a cohesive workflow.

To help customers interpret these vastly richer discoveries, BioSkryb is investing in AI and machine learning to integrate single cell multiomic data into interpretable features and novel biomarker candidates—an emerging need as multi-omic single-cell datasets grow in scale and complexity.

“Bringing non-destructive, same-cell methylation together with variant analysis moves single-cell biology from partial snapshots to a more complete molecular picture,” said Charles (Chuck) Gawad, MD, PhD, Chief Scientific Officer and Founder, BioSkryb Genomics. “When epigenetic state and genetic variation are measured in concert, researchers can connect cause and consequence in ways that accelerate discovery and, ultimately, precision medicine.”

“At CZ Biohub SF, our mission is to accelerate discovery and responsibly translate breakthroughs for broad public benefit,” said Melinda Griffith, Chief Operating Officer, Biohub SF. “Licensing this invented method to BioSkryb enables wider access to combined single-cell methylation and variant analysis, supporting researchers and, ultimately, patients.”